Boston Scientific Co. (NYSE:BSX) Position Lessened by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System decreased its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 4.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 79,300 shares of the medical equipment provider's stock after selling 3,600 shares during the quarter. Louisiana State Employees Retirement System's holdings in Boston Scientific were worth $7,083,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Global Wealth Strategies & Associates boosted its position in shares of Boston Scientific by 423.7% during the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock valued at $28,000 after buying an additional 250 shares during the last quarter. West Oak Capital LLC bought a new position in Boston Scientific in the 4th quarter worth approximately $29,000. Dunhill Financial LLC grew its stake in Boston Scientific by 86.4% during the third quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock valued at $28,000 after acquiring an additional 152 shares in the last quarter. Values First Advisors Inc. purchased a new position in Boston Scientific during the third quarter worth about $28,000. Finally, E Fund Management Hong Kong Co. Ltd. purchased a new stake in Boston Scientific in the third quarter valued at approximately $30,000. Institutional investors own 89.07% of the company's stock.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig sold 4,877 shares of Boston Scientific stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $91.63, for a total value of $446,879.51. Following the completion of the transaction, the director now directly owns 39,398 shares in the company, valued at approximately $3,610,038.74. This trade represents a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Arthur C. Butcher sold 14,010 shares of the company's stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the sale, the executive vice president now directly owns 978 shares in the company, valued at approximately $87,306.06. This represents a 93.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 53,830 shares of company stock valued at $5,149,969 in the last ninety days. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Trading Down 0.2 %

Boston Scientific stock traded down $0.18 during midday trading on Wednesday, reaching $105.80. 5,456,226 shares of the stock traded hands, compared to its average volume of 6,164,861. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. Boston Scientific Co. has a 12-month low of $64.54 and a 12-month high of $107.17. The firm has a market cap of $155.93 billion, a PE ratio of 84.64, a price-to-earnings-growth ratio of 2.79 and a beta of 0.80. The company has a 50-day simple moving average of $95.50 and a two-hundred day simple moving average of $87.72.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. Research analysts expect that Boston Scientific Co. will post 2.83 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. TD Cowen boosted their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Thursday, December 12th. StockNews.com raised Boston Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, January 29th. JPMorgan Chase & Co. raised their price objective on Boston Scientific from $100.00 to $110.00 and gave the stock an "overweight" rating in a research note on Monday, December 16th. Piper Sandler increased their price objective on shares of Boston Scientific from $95.00 to $115.00 and gave the company an "overweight" rating in a report on Monday, February 3rd. Finally, Morgan Stanley upped their price target on shares of Boston Scientific from $100.00 to $120.00 and gave the company an "overweight" rating in a research note on Thursday, February 6th. One analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $107.39.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.